Jana Mihalyova

Ostrava, MO, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.

Journal: HemaSphere
Published: May 20, 2026

Teclistamab in relapsed/refractory Waldenström macroglobulinemia

Teclistamab in relapsed/refractory Waldenström macroglobulinemia

Journal: Haematologica
Published: April 28, 2026

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Journal: Blood advances
Published: December 01, 2025

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.

Journal: Blood advances
Published: December 01, 2025

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Journal: Annals of hematology
Published: August 10, 2025

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Journal: Blood cancer journal
Published: July 08, 2025

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.

Journal: HemaSphere
Published: June 21, 2025

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 10, 2025

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.

Journal: Annals of hematology
Published: May 28, 2025

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Journal: Blood cancer discovery
Published: May 15, 2025

The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.

The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.

Journal: HemaSphere
Published: April 29, 2025

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Journal: Blood
Published: April 14, 2025
Showing 1-12 of 29

Last Updated: 09/26/2026